GOV Stock Overview
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Insulet Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$262.30 |
| 52 Week High | US$313.45 |
| 52 Week Low | US$176.24 |
| Beta | 0.74 |
| 1 Month Change | -4.60% |
| 3 Month Change | -7.93% |
| 1 Year Change | 28.64% |
| 3 Year Change | 82.15% |
| 5 Year Change | 286.99% |
| Change since IPO | 2,190.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| GOV | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -2.6% | 0.3% | -1.1% |
| 1Y | 28.6% | -6.0% | -4.9% |
Return vs Industry: GOV exceeded the German Medical Equipment industry which returned -6% over the past year.
Return vs Market: GOV exceeded the German Market which returned -4.9% over the past year.
Price Volatility
| GOV volatility | |
|---|---|
| GOV Average Weekly Movement | 3.5% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 9.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: GOV is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: GOV's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 2,600 | Jim Hollingshead | https://www.insulet.com |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia.
Insulet Corporation Fundamentals Summary
| GOV fundamental statistics | |
|---|---|
| Market Cap | €18.32b |
| Earnings (TTM) | €4.32m |
| Revenue (TTM) | €1.23b |
4,238x
P/E Ratio14.9x
P/S RatioIs GOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GOV income statement (TTM) | |
|---|---|
| Revenue | US$1.31b |
| Cost of Revenue | US$499.70m |
| Gross Profit | US$805.60m |
| Other Expenses | US$801.00m |
| Earnings | US$4.60m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.066 |
| Gross Margin | 61.72% |
| Net Profit Margin | 0.35% |
| Debt/Equity Ratio | 294.2% |
How did GOV perform over the long term?
See historical performance and comparison